Evidence map›Paper›PMID 40985024›Full record

ArticleInternational journal of cardiology. Heart & vasculature2025

Fibrinogen-to-albumin ratio as a novel biomarker for risk assessment in clinically suspected acute myocarditis.

Lihi Levi-Gofman, Shaul Atar, Gassan Moady

Abstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. A novel parameter for risk stratification in patients with takotsubo syndrome.American heart journal plus : cardiology research and practice · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lihi Levi-GofmanAzrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Shaul AtarAzrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Gassan MoadyAzrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute myocarditis typically follows a benign course, but fatal complications may occur in fulminant cases. Evaluation is based on clinical, laboratory, and imaging parameters. We aimed to assess the prognostic value of the fibrinogen-to-albumin ratio (FAR) in patients with clinically suspected myocarditis. Methods: Echocardiographic, laboratory, and clinical parameters were obtained from patients with clinically suspected myocarditis. We assessed the correlations between troponin, albumin, fibrinogen, FAR, left ventricular ejection fraction (LVEF), and complications during the index hospitalization. Repeat echocardiography was performed in patients with reduced LVEF. Several potential factors were tested for their ability to predict LVEF recovery. Results: A total of 118 patients were included (80 % male; median age, 35 years; mean LVEF, 55 %). Median troponin level was 2558 ng/L, and the median fibrinogen-to-albumin ratio (FAR) was 120. In 38 patients (32 %), LVEF was reduced; among them, 15 (39 %) had persistently reduced LVEF on repeat echocardiography. Troponin levels and FAR were inversely correlated with reduced LVEF (r = -0.28, p = 0.002 and r = -0.31, p = 0.001, respectively). FAR remained an independent factor after adjustment for age and sex. Neither troponin nor FAR was associated with persistently reduced LVEF on follow-up echocardiography. In addition, high FAR was not correlated with longer length of stay (LOS) (p = 0.07), readmissions (p = 0.29), or complications during hospitalization (p = 0.22). Conclusion: FAR is associated with reduced LVEF and may reflect disease severity in clinically suspected myocarditis; however, it does not appear to be useful for long-term prediction.

Indexed as

AlbuminFibrinogenMyocarditisOutcomes

Identifiers

PMID40985024
PMCPMC12450558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.